Nasivin, 0.05% drops 10 ml

Nasivin® (oxymetazoline) has a vasoconstrictor effect. When applied topically on inflamed nasal mucosa it reduces its swelling and nasal discharge. It restores nasal breathing.

The removal of mucous membrane edema restores aeration of paranasal sinuses, middle ear cavity which prevents the development of bacterial complications (maxillary sinusitis, sinusitis, otitis media).

When applied locally intranasally in therapeutic concentrations the drug does not irritate mucosa and does not cause hyperemia. When administered locally intranasally the drug has no systemic action. The drug begins to act quickly (within a few minutes). The duration of action of Nazivin is up to 12 hours.

Indications

– Treatment of acute respiratory diseases accompanied by a runny nose;

– allergic rhinitis;

– vasomotor rhinitis;

– to restore drainage in case of inflammation of the paranasal sinuses, eustachitis, otitis media;

– to eliminate swelling before diagnostic manipulations in the nasal passages.

Pharmacological effect

Nazivin® (oxymetazoline) has a vasoconstrictor effect. When applied topically to the inflamed nasal mucosa, it reduces swelling and nasal discharge. Restores nasal breathing.

Elimination of mucosal edema helps restore aeration of the paranasal sinuses and middle ear cavity, which prevents the development of bacterial complications (sinusitis, sinusitis, otitis media).

When used locally intranasally in therapeutic concentrations, it does not irritate the mucous membrane and does not cause hyperemia. When administered locally intranasally, the drug does not have a systemic effect. The drug begins to act quickly (within a few minutes). The duration of action of Nazivin is up to 12 hours.

Special instructions

Long-term use and overdose of the drug should be avoided, especially in children.

After long-term use or administration of cold remedies containing oxymetazoline in dosages exceeding the recommended ones, a general effect on the cardiovascular system and central nervous system cannot be excluded.

Active ingredient

Oxymetazoline

Composition

1 ml of the drug contains:

Active substance:

Nazivin 0.01% – Oxymetazoline hydrochloride 0.1 mg

Nazivin 0.025% – Oxymetazoline hydrochloride 0.25 mg

Nazivin 0.05% – Oxymetazoline hydrochloride 0.5 mg

Excipients:

benzalkonium chloride 50% solution,

disodium edetate dihydrate,

sodium dihydrogen phosphate dihydrate,

sodium hydrogen phosphate dihydrate,

sodium hydroxide 1 M solution,

purified water.

Pregnancy

When used during pregnancy or breastfeeding, do not exceed the recommended dosage.

Contraindications

Atrophic rhinitis; angle-closure glaucoma; hypersensitivity to the components of the drug. You should adhere to the recommended concentrations of the drug intended for different age categories (see methods of use).

With caution

In patients taking monoamine oxidase inhibitors and other drugs that increase blood pressure for up to 10 days after their use; with increased intraocular pressure, during pregnancy and lactation, with severe forms of cardiovascular diseases (hypertension, angina); with thyrotoxicosis and diabetes mellitus.

Side Effects

Sometimes: burning or dryness of the nasal membranes, sneezing.

In rare cases: after the effect of using Nazivin® wears off, a strong feeling of “stuffiness” in the nose (reactive hyperemia). Repeated overdose with local nasal use sometimes leads to such systemic sympathomimetic effects as increased heart rate (tachycardia) and increased blood pressure.

In very rare cases, anxiety, insomnia, fatigue, headaches and nausea have been observed.

Long-term continuous use of vasoconstrictor drugs can lead to tachyphylaxis, atrophy of the nasal mucosa and recurrent swelling of the nasal mucosa (rhinitis medicamentosa).

Interaction

When MAO blockers and tricyclic antidepressants are prescribed simultaneously, blood pressure increases.

Overdose

Symptoms (after a significant overdose or accidental ingestion): constriction of the pupils, nausea, vomiting, cyanosis, increased body temperature, tachycardia, arrhythmia, vascular insufficiency, arterial hypertension, respiratory disorders, pulmonary edema, cardiac arrest; in addition, mental disorders may appear, as well as depression of central nervous system functions, accompanied by drowsiness, decreased body temperature, bradycardia, arterial hypotension, respiratory arrest and possible development of coma.

Treatment: gastric lavage, taking activated carbon and urgently consulting a doctor.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

Sofarimex Industria Kimica e Pharmasuetica S.A., Portugal